Skip to main content
OpenTrials
Completed

NCT Number: NCT04122118

Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor

This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malignant Solid Neoplasm

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

About this study

PRIMARY OBJECTIVE:

I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s.

SECONDARY OBJECTIVE:

I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education.

EXPLORATORY OBJECTIVE:

I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial.

OUTLINE:

PHASE I: Patients' medical records are reviewed.

PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.

After completion of study, patients are followed up periodically.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Solid tumor diagnosis
  • Starting day 1 of new antineoplastic infusion
  • English speaking (and/or English-speaking primary caregiver/proxy)

Exclusion criteria

  • Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition
  • Severe cognitive impairment including dementia with inability to consent to the study

Treatment and study plan

medical chart review

Other

Review of medical chart

Other names: Chart Review

Educational Intervention

Other

Receive pharmacist-led education

Other names: Education for Intervention, Intervention by Education, Intervention through Education, Educational

Survey Administration

Other

Ancillary studies

Primary outcomes

  1. Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)

    Time frame: Up to 1 year

    MRPs will be assigned to a specific category and the total number of MRPs in each category will be recorded. Categories include but are not limited to: incorrect dose, therapeutic duplication, drug not indicated, drug interaction, monitoring recommendation, drug allergy, or potential for adverse event.

  2. Percent of MRPs corrected as a result of the clinical oncology pharmacist services (Phase II)

    Time frame: Up to 1 year

    In phase 2 (prospective) MRPs will also be recorded and categorized, but in addition the outcomes relating to each MRP pharmacist intervention will be recorded. MRPs found by the pharmacist will be communicated to the patient's oncologist or primary care provider, and the pharmacist will follow-up to see if changes were made.

Secondary outcomes

  1. Patient and provider satisfaction with the pharmacist-led education

    Time frame: Up to 1 year

    The survey results will help determine the need for a clinical oncology pharmacist in the outpatient infusion center. Satisfaction will be assessed using a Likert-scale survey. Scale ranges from 1 (strongly disagree) to 5 (strongly agree).

Other outcomes

  1. Estimate of Cost avoidance utilizing pharmacy services

    Time frame: Up to 1 year

    In order to determine cost avoidance the type of interventions made and the time associated with each intervention will be recorded. The cost per intervention will be calculated by multiplying the pharmacist salary in minutes by the time for each intervention. The intervention types will be assigned cost avoidance values based on previous literature and these will be used to determine the cost benefit for the interventions made during the study period.

Sponsors and collaborators

Lead sponsor

Thomas Jefferson University

Other

Registry information

Official study title

Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Oct 10, 2019
Registry last updated
Apr 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.